CATEGORY

Viral Vaccines

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Viral Vaccines.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Category Alerts


CATEGORY ALERTS

Vaccizone has chosen Exothera to handle the process development and GMP manufacturing of its SARSCoV2 vaccine, which is based on proprietary ASC technology.

July 13, 2022
alert level: Medium
CATEGORY ALERTS

WuXi Vaccines Received Ireland Health Products Regulatory Authority's First GMP Certificate of QC Potency Lab

July 21, 2022
alert level: Medium
CATEGORY ALERTS

The European Commission has approved a purchase agreement amendment for Valneva's inactivated COVID-19 vaccine.

July 27, 2022
alert level: Medium

Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Viral Vaccines

Viral Vaccines Market Monitoring Dashboard


Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Viral Vaccines Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Viral Vaccines category is 2.50%

Payment Terms

(in days)

The industry average payment terms in Viral Vaccines category for the current quarter is 90.0 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Viral Vaccines Suppliers


    1,239 
    Total Suppliers
    42
    Diverse Suppliers
    73
    Normalized Supplier Rating
    Viral Vaccines Supplier

    Find the right-fit viral vaccines supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Viral Vaccines market report transcript


    Viral Vaccines Global Market Outlook

    There is an increasing awareness of immunization and a inspiration to formulate strong vaccine pipeline and the increasing focus of the key pharmaceutical players to develop innovative vaccines. These factors are driving the market with a CAGR of 8.7 percent and is expected to reach $81.27 billion by the end of 2027.

    The market dynamics of research chemistry can be understood from the demand–supply perspective

    • From the demand side, pharmaceutical companies are facing pipeline issues and outsourcing additional activities. This trend has led to the emergence of outsourcing of production services, with emerging nations like India and China becoming favorable destinations
    • The viral vaccine production function is highly outsourced to leverage technical expertise and specific therapeutic area skill set at CROs

    viral-vaccine

    Regional Market Share 

    It is easier to offshore more routine services, like Live-attenuated vaccine production and Subunit Vaccine production, to emerging regions, like India and China. However, services, like Toxiod Vaccines and Conjugated Vaccine Production that require strict regulatory guidelines, are mostly near shored to the developed markets

    • This is expected to change in the future with suppliers, like Wuxi AppTec, building capabilities in technologies, like computer-aided drug development and identify potential drug candidates in lesser time. Such factors will expedite the drug development process
    • Western markets are mainly involved in the niche service for chemistry function, whereas the transactional/routine functions under chemistry services are generally outsourced to the emerging market.